Do You Own Celgene Corporation (NASDAQ:CELG) Shares?


Celgene Corporation (NASDAQ:CELG) closed its last session at $94.39. The stock traded within a range of $91.90 and $94.70. The company operates in the Healthcare sector with a market capitalization of 73.12 Million. Trading volume for Celgene Corporation was 6.94 Million in its previous trading session. Currently, Celgene Corporation (NASDAQ:CELG) has an average volume of 7.09 Million.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Analyst Views

Celgene Corporation (NASDAQ:CELG) received a Buy rating from 6 analysts. 1 analysts gave its stock an Outperform rating. 3 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

Celgene Corporation (NASDAQ:CELG) touched its 1-Year High price of $147.17 on 10/02/17 and its 1-Year Low price of $ 88.32 on 02/09/18.

EPS & Financials

Celgene Corporation (NASDAQ:CELG) reported its EPS in the last quarter as $2/Share beating the analyst estimate of $1.97/Share by a difference of $0.03. This showed a surprise of 1.5% in the last quarter earnings.

For the current quarter, 23 analysts are projecting a mean EPS of $1.95/share. According to their observations and findings, the stock could provide a high EPS of $2.12/share and a low EPS of $1.62/share.

Analysts believe that the company has the potential to earn average revenue of $3.45 Billion for the current quarter. According to their predictions high & low revenue estimates are 3.6 Billion and 3.3 Billion respectively.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. Celgene Corporation (NASDAQ:CELG) has a 20-Day average volume of 8.59 Million. According to today’s trading volume Celgene Corporation is BELOW its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.2 Percent and Institutional ownership of 81.1 Percent. The return on assets stands at 9.7%, Return on Equity currently is 35.8% and the Return on Investment value is 21.2%.

Celgene Corporation (NASDAQ:CELG) gross margin percentage stands at 96.5% while its operating margin for the past trailing twelve month is 35.8 percent and its overall profit margin (ttm) is 22.6 Percent. The stock is currently moving below its 20-Day Simple Moving Average of -4.89% with a 50-Day Simple Moving Average of -8.57 percent. As of today, the company has a SMA200 (200-day simple moving average) of -21.63 Percent. The Stock has YTD (year to date) performance of -9.55 percent.

The TTM operating margin for the company stands at 35.8%. The return on invested capital is at 21.2%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 14.72.

The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -21.63%, and has a solid year to date (YTD) performance of -9.55% which means that the stock is constantly adding to its value from the previous fiscal year end price.